![PDF) The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience PDF) The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience](https://i1.rgstatic.net/publication/293169129_The_Dohner_fluorescence_in_situ_hybridization_prognostic_classification_of_chronic_lymphocytic_leukaemia_CLL_The_CLL_Research_Consortium_experience/links/5a0bf1f2458515e48275027f/largepreview.png)
PDF) The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience
Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response Cancers | Free Full-Text | Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response](https://www.mdpi.com/cancers/cancers-13-00257/article_deploy/html/images/cancers-13-00257-g001.png)
Cancers | Free Full-Text | Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response
![Slc11a1 gene polymorphism influences dextran sulfate sodium (DSS)-induced colitis in a murine model of acute inflammation | Genes & Immunity Slc11a1 gene polymorphism influences dextran sulfate sodium (DSS)-induced colitis in a murine model of acute inflammation | Genes & Immunity](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41435-023-00199-7/MediaObjects/41435_2023_199_Fig1_HTML.png)
Slc11a1 gene polymorphism influences dextran sulfate sodium (DSS)-induced colitis in a murine model of acute inflammation | Genes & Immunity
![A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia | Leukemia A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-023-01830-2/MediaObjects/41375_2023_1830_Fig1_HTML.png)